PD-L1 upregulation accompanied with epithelial–mesenchymal transition attenuates sensitivity to ATR inhibition in p53 mutant pancreatic cancer cells
Sign Up to like & getrecommendations! Published in 2020 at "Medical Oncology"
DOI: 10.1007/s12032-020-01372-y
Abstract: Pancreatic cancer is a highly progressive malignant tumor for which there is a critical unmet need for novel therapeutic strategies. A previous study of the authors indicated that VE-821, a selective inhibitor of the ataxia-telangiectasia-mutated and… read more here.
Keywords: mutant pancreatic; inhibition; pancreatic cancer; sensitivity ... See more keywords
Abstract 1218: Synthetic lethal targeting of p53 mutant cells with prenylation inhibitors
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-1218
Abstract: Introduction: TP53 is mutated in 30-40% of breast cancers and is associated with poor prognosis. Mutation of TP53 causes increased cellular proliferation, migration and invasion, and downstream activation of multiple pathways. HMG CoA reductase inhibitors,… read more here.
Keywords: p53 mutant; prenylation inhibitors; p53; prenylation ... See more keywords
Abstract 5805: Palbociclib synergistically enhances the anticancer activity of cisplatin in P53 mutant model of upper gastrointestinal cancers
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-5805
Abstract: Background: Upper Gastrointestinal Cancers (UGCs) respond poorly to conventional chemotherapy due to overactive intrinsic mechanisms that mediate cellular proliferation and drug resistance. Dysregulated cell division due to increased activity of cyclin-dependent kinases 4/6 (CDK4/6) is… read more here.
Keywords: palbociclib; upper gastrointestinal; p53 mutant; gastrointestinal cancers ... See more keywords
Lipidome atlas of p53 mutant variants in pancreatic cancer
Sign Up to like & getrecommendations! Published in 2025 at "Biology Direct"
DOI: 10.1186/s13062-025-00635-w
Abstract: Mutations in the tumour suppressor protein p53 are present in 70% of human pancreatic ductal adenocarcinomas (PDAC), subsequently to highly common activation mutation of the oncogene KRAS. These p53 mutations generate stable expression of mutant… read more here.
Keywords: lipidome atlas; mutant variants; p53 mutant; p53 ... See more keywords
Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer
Sign Up to like & getrecommendations! Published in 2019 at "Cancers"
DOI: 10.3390/cancers11040462
Abstract: The implementation of cancer immunotherapeutics for solid tumors including lung cancers has improved clinical outcomes in a small percentage of patients. However, the majority of patients show little to no response or acquire resistance during… read more here.
Keywords: mesenchymal kras; p53 mutant; checkpoint; cancer ... See more keywords